Home › Compare › NEVPF vs GBDC

NEVPF vs GBDC: Dividend Comparison 2026

NEVPF yields 7142.86% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEVPF wins by $2020155342665710.50M in total portfolio value
10 years
NEVPF
NEVPF
● Live price
7142.86%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2020155342665731.25M
Annual income
$1,966,011,161,323,515,200,000.00
Full NEVPF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — NEVPF vs GBDC

📍 NEVPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEVPFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEVPF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NEVPF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEVPF
Annual income on $10K today (after 15% tax)
$607,142.86/yr
After 10yr DRIP, annual income (after tax)
$1,671,109,487,124,987,800,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, NEVPF beats the other by $1,671,109,487,124,974,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEVPF + GBDC for your $10,000?

NEVPF: 50%GBDC: 50%
100% GBDC50/50100% NEVPF
Portfolio after 10yr
$1010077671332876.00M
Annual income
$983,005,580,661,765,800,000.00/yr
Blended yield
97.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

NEVPF
No analyst data
Altman Z
-0.7
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEVPF buys
0
GBDC buys
0
No recent congressional trades found for NEVPF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEVPFGBDC
Forward yield7142.86% ✓11.85%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$2020155342665731.25M ✓$20.78M
Annual income after 10y$1,966,011,161,323,515,200,000.00 ✓$16,389,263.41
Total dividends collected$2016528271361529.00M ✓$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: NEVPF vs GBDC ($10,000, DRIP)

YearNEVPF PortfolioNEVPF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$724,986$714,285.71$12,490$1,790.28+$712.5K → NEVPF
2$49,172,645$48,396,910.17$16,522$3,157.73+$49.16M → NEVPF
3$3,120,421,331$3,067,806,600.72$23,578$5,898.68+$3120.40M → NEVPF
4$185,281,229,916$181,942,379,091.82$37,115$11,886.75+$185281.19M → NEVPF
5$10,294,691,143,508$10,096,440,227,497.77$66,136$26,423.57+$10294691.08M → NEVPF
6$535,299,070,050,255$524,283,750,526,701.75$137,257$66,491.44+$535299069.91M → NEVPF
7$26,050,796,629,539,330$25,478,026,624,585,550.00$341,734$194,868.54+$26050796629.20M → NEVPF
8$1,186,669,129,317,434,600$1,158,794,776,923,827,700.00$1,050,788$685,133.02+$1186669129316.38M → NEVPF
9$50,602,038,637,584,920,000$49,332,302,669,215,270,000.00$4,099,314$2,974,971.01+$50602038637580.82M → NEVPF
10$2,020,155,342,665,731,300,000$1,966,011,161,323,515,200,000.00$20,775,530$16,389,263.41+$2020155342665710.50M → NEVPF

NEVPF vs GBDC: Complete Analysis 2026

NEVPF — Stock

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Full NEVPF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this NEVPF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEVPF vs SCHDNEVPF vs JEPINEVPF vs ONEVPF vs KONEVPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.